ubmslateOT-logo-ubm

OT mobile menu

Topics:

Home

ASCO 2015: Nivolumab Improves Response Rates for Metastatic NSCLC

In this article, we discuss the overall response rate from nivolumab in metastatic squamous NSCLC.

Nivolumab showed greater overall survival in patients with metastatic squamous NSCLC, - See more at: http://www.oncotherapynetwork.com/asco-2015/nivolumab-improves-response-...

Recent Content

Researchers at the University of North Carolina (UNC) Lineberger Comprehensive Cancer Center have identified the potential of protein called CIB1 as a new drug target for patients with an aggressive form of breast cancer.

Two large-scale precision medicine clinical trials for lung cancer are underway in the United States, and offer potential new treatment options for patients with specific genetic mutations.

Sarcomas are a heterogeneous and motley collection of cancers, which struggle with an identity crisis on many levels. The trials often lump vastly different subgroups, and are often unable to collect sufficient numbers of any one disease subtype to complete a unique cohort.

Researchers at Memorial Sloan Kettering Cancer Center (MSKCC) have created a tiny device that can deliver cancer therapies directly to the tumor site. What's more, this technology could potentially treat chemotherapy-induced kidney failure.

Adding necitumumab (IMC-11F8) to gemcitabine (Gemzar) and cisplatin chemotherapy may improve overall survival (OS) in patients with advanced squamous non-small cell lung cancer, according to new phase III clinical trial results published in Lancet Oncology.

A 63-year-old man presents with a mass in the left kidney. After further evaluation, a biopsy is performed. What is your diagnosis?

Advanced imaging techniques could allow clinicians the ability to determine as early as 9 days into sarcoma treatment whether the therapy will be effective in a given patient, according to a new University of Michigan study.

By clicking Accept, you agree to become a member of the UBM Medica Community.